Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants : Journal of Immunotherapy

Secondary Logo

Journal Logo

You can read the full text of this article if you:

Access through Ovid
Original Study

Efficacy and Safety of Immune Checkpoint Inhibitors in Triple-negative Breast Cancer: A Study Based on 41 Cohorts Incorporating 6558 Participants

Wu, Qing*,†; Wu, Chunlan*,†; Xie, Xianhe*,†,‡

Author Information
Journal of Immunotherapy: November 16, 2022 - Volume - Issue - 10.1097/CJI.0000000000000447
doi: 10.1097/CJI.0000000000000447
  • Buy
  • SDC
  • PAP

Abstract

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.